Biomarkers in gastrointestinal stromal tumor: Should we equate blood-based pharmacodynamics with tumor biology and clinical outcomes?

Clinical Cancer Research

Volumn 13, Issue 9, 2007, Pages 2535-2536

  McAuliffe, John C ^a   Trent, Jonathan C ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; DOXORUBICIN; IMATINIB; PROSTATE SPECIFIC ANTIGEN; PROTEIN BCL 2; STEM CELL FACTOR; SUNITINIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

EDITORIAL; GASTROINTESTINAL TUMOR; HISTOPATHOLOGY; HUMAN; MEDICAL RESEARCH; ONCOGENE; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; GASTROINTESTINAL STROMAL TUMORS; HUMANS; SURVIVAL; TREATMENT OUTCOME;

EID: 34249002081     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-0364     Document Type: Editorial

References (16)

1. Norden-Zfoni A, Desai J, Manola J, et al. Blood-based biomarkers of SU11248 activity and clinical outcome in patients with metastatic imatinib-resistant gastrointestinal stromal tumor. Clin Cancer Res 2007; 13:2643-50.
2. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004; 364:1127-34.
3. Trent JC, Beach J, Burgess MA, et al. A two-arm phase II study of temozolomide in patients with advanced gastrointestinal stromal tumors and other soft tissue sarcomas. Cancer 2003;98:2693-9.
4. Hill AB. The environment and disease: association or causation? J R Soc Med 1965;58:295-300.
5. Eisenberger MA, Nelson WG. How much can we rely on the level of prostate-specific antigen as an end point for evaluation of clinical trials? A word of caution! J Natl Cancer Inst 1996;88:779-81.
6. Boissel JP, Collet JP, Moleur P, Haugh M. Surrogate endpoints: a basis for a rational approach. Eur J Clin Pharmacol 1992;43:235-44.
7. Park JW, Kerbel RS, Kelloff GJ, et al. Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development. Clin Cancer Res 2004;10:3885-96.
8. Kuwana M, Okazaki Y, Kodama H, Satoh T, Kawakami Y, Ikeda Y. Endothelial differentiation potential of human monocyte-derived multipotential cells. Stem Cells 2006;24:2733-43.
9. Bertolini F, Paul S, Mancuso P et al. Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. Cancer Res 2003;63:4342-6.
10. Shaked Y, Ciarrocchi A, Franco M, et al. Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors. Science 2006;313: 1785-7
11. Zhang H, Vakil V, Braunstein M, et al. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood 2005;105: 3286-94.
12. Dome B, Timar J, Dobos J, et al. Identification and clinical significance of circulating endothelial progenitor cells in human non-small cell lung cancer. Cancer Res 2006;66:7341-7.
13. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006;42:1093-103.
14. Nilsson B, Beumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era - a population-based study in western Sweden. Cancer 2005;103:821-9.
15. Steinert DM, Oyarzo M, Wang X, et al. Expression of Bcl-2 in gastrointestinal stromal tumors: correlation with progression-free survival in 81 patients treated with imatinib mesylate. Cancer 2006;106: 1617-23.
16. Chirieac LR, Trent JC, Steinert DM, et al. Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate. Cancer 2006;107: 2237-44.